John K. Scott Jr. is 10% Owner at NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB). They have made 5 open-market trades across 1 company since 2019, most recently 2023-11-27.
CIK 0001753763
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $8.2M since 2019, never a sale. Across 5 scored buys the stock is down 7.5% at ninety days, and 5.1 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| NAVB | 31,755,832 | $2.5M |
Shares reported on the most recent Form 4, priced at the 2023-06-30 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 40% | 20% | 40% |
| Avg Move | -6.7% | -2.7% | -7.5% |
| Alpha | -5.3% | +3.2% | -5.1% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NAVB | BUY | 2020-08-30 | 2020-09-02 | $5.00 | $25K | +2.4% | -6.3% | -19.1% |
| NAVB | BUY | 2020-02-13 | 2020-02-19 | $0.85 | $4.0M | -8.7% | -28.4% | +33.9% |
| NAVB | BUY | 2019-12-06 | 2019-12-11 | $0.90 | $1000K | +1.4% | +45.7% | -5.6% |
| NAVB | BUY | 2019-06-18 | 2019-06-21 | $0.75 | $3.0M | -17.9% | -19.4% | +26.0% |
| NAVB | BUY | 2019-03-22 | 2019-03-25 | $0.14 | $100K | -10.6% | -5.1% | -72.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.